SCHEMBL30749088

SCHEMBL30749088

C=C(C)c1cnn2cc(Br)cnc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 3/20 0.36
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
TDP1 Q9NUW8 4/20 0.35
POLB P06746 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 1/20 0.34
PDE2A O00408 5/20 0.33
PDE10A Q9Y233 1/20 0.33
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
DYRK3 O43781 1/20 0.33
MAP4K4 O95819 1/20 0.33
NTRK1 P04629 1/20 0.33
INSR P06213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13960990 0.73 KDR (0.37) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL14033767 0.73 ALDH1A1 (0.55) TDP1POLBSMN1; SMN2MAPTLMNA
SCHEMBL3754835 0.72 PRKAB2 (0.54) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL22047582 0.71 SMPD3 (0.51) IRAK4SMN1; SMN2CDK2LMNAKDM4E
SCHEMBL3772458 0.69 PRKAB2 (0.37) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL31487914 0.69 MAPT (0.38) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL28566342 0.69 MAOB (0.39) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL30749069 0.69 PLK4 (0.35) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL15333581 0.69 POLB (0.43) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL19265949 0.69 PRKAB2 (0.37) IRAK4PRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT IRAK4 3322/4885PRKAB2 3672/4885PRKAG1 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.